Kornimate/medical-research-clean huggingface dataset:
neutrophil phenotypic profiling and acute lung injury in patients after cardiopulmonary bypass (cpb)

Conditions: Lung Injury; Cardiopulmonary Bypass

Summary: acute lung injury (ali) following cardiopulmonary bypass (cpb) is a serious complication, often prolonging the length of stay in icu and potentially dealing to mortality. the objective of this study is to assess the mechanism of cpb-mediated acute lung injury in pediatric patients.

acute lung injury (ali) is frequently associated with the use of extracorporeal circulation during cardiopulmonary bypass (cpb) surgery and develops postoperatively in 2-3% of cardiac surgical patients. histological evidence shows that cpb increases pulmonary vascular permeability and extravascular lung water content while diminishing pulmonary compliance. furthermore, some patients can develop acute respiratory distress syndrome, which has a mortality rate of 50-70%. recruitment of intrapulmonary neutrophils is a characteristic of ali following cpb. blood contact with non-physiological surfaces, cooling and rewarming and mechanical shear stress activate neutrophils. the recruitment of activated neutrophils from blood vessels to local tissue involves a chain of well-coordinated events, including adhesion, tethering, rolling and crawling, followed by trans-endothelial and trans-epithelial migration. activation of sequestered neutrophils causes the release of specific proteolytic enzymes and oxygen free radicals, which leads to increased alveolar-endothelial permeability and parenchymal damage. during cpb, the lungs are almost completely excluded from the systemic circulation, which causes the blood within them to be almost 'static'. pulmonary tissue hypoxia and re-oxygenation combined with vascular ischemia and reperfusion induce the generation of chemokines, which contributes to subsequent injury by accumulating and entrapping activated neutrophils. the accumuled and entrapped activated neutrophils in the lungs and the subsequent release of toxic substances render the lungs highly susceptible to this damage. however, the mechanism that drives neutrophil migration to the lungs after cpb is not well studied. this study will delineate the mechanisms of neutrophil migration to the lung and subsequent lung injury after cpb.

Eligibility criteria:
inclusion criteria: * are \< 12months of age * scheduled for cardiac surgical needing cpb * preoperative spo2 \> 90% exclusion criteria: * lack of parental (or legal guardian's) consent * preoperative spo2 \< 90% * preoperative oxygen therapy
igg-mediated food test for weight loss

Conditions: Overweight and Obesity

Summary: this study assessed the effect of an igg-mediated food sensitivity test in combination with a food elimination diet on body composition and secondary outcomes in people who were overweight.

this study looked at foods that stimulated igg food antibody production, which may play a role in certain conditions, such as irritable bowel syndrome, obesity, type i diabetes, and migraine headaches. using a proprietary blood test, the immuno bloodprint, to determine which foods stimulate igg food antibodies in each person, this study detailed a personalized list of reactive foods that stimulated such antibodies for each participant. the participant was then advised to eliminate as much as possible the reactive foods for 90 days.

Eligibility criteria:
inclusion criteria: * bmi above 20 * express an interest in losing weight exclusion criteria: * less than 18 years of age * currently participating in another research trial for weight loss * suffering from serious medical complications that might limit their participation, such as recent heart attack, stroke, or chronic kidney disease * pregnant

Keywords: food sensitivity igg obesity overweight body composition reactive foods
venous thromboembolism taskforce audit program

Conditions: Venous Thrombosis

Summary: to determine the effect of an interventional campaign run by a dedicated "vte nurse educator" over a 6-month period and the effect on prophylaxis rates. to determine the proportion of medically admitted patients with risk factors for vte. to assess and compare the use of venous thromboembolism (vte) prophylaxis in hospitalized medical patients versus recommendations and current guidelines. to determine the patient characteristics of those deemed to be at risk of vte. to determine the proportion of patients receiving appropriate thromboprophylaxis for their risk. to determine the type and duration (where possible) of prophylaxis used.


Eligibility criteria:
inclusion criteria: * hospital admission for an acute illness with an in-patient hospital stay of 3 days or more. exclusion criteria: * patients who have undergone any type of surgery during current admission * patients who are admitted to a ward or department that is excluded from this study e.g psychiatric, paediatric, maternity, intensive care unit, coronary care unit. * prior enrollment in this protocol during current admission * prior enrollment in a vte study involving pharmaceutical or mechanical treatment within last 90 days. * admission for suspected or diagnosed deep vein thrombosis the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
tiva, inhalation anesthesia, and surgical site infection

Conditions: Colorectal Disorders

Summary: the purpose of this retrospective study was to evaluate the incidence of ssi after colorectal surgery under the general anesthesia by different general anesthetic technique: inhalation versus total intravenous anesthesia.


Eligibility criteria:
inclusion criteria: * adult patients who underwent elective colorectal surgery under general anesthesia from january 2011 to december 2013. exclusion criteria: * none
safety and efficacy of an adult acute lymphoblastic leukemia chemotherapy for adult lymphoblastic lymphoma

Conditions: Lymphoblastic Lymphoma

Summary: the primary objective of this study is to evaluate the safety and the efficacy of an adult "acute lymphoblastic leukaemia" type chemotherapy in patients less than 60 years with lymphoblastic lymphoma. treatment principle is based on an intensive induction and a delayed intensification.

lymphoblastic lymphomas (ll) are rare and represent less than 2% of the malignant non-hodgkin lymphomas (nhl). the distinction between a ll and an acute lymphoblastic leukaemia (all) is difficult; it is arbitrarily based on the percentage of medullary blasts. above 20% of blasts, it is an all. in both cases, the same type of cells is affected: the lymphoblast. thus the ll were treated either as aggressive nhl or as all. the results of the various clinical studies, have shown a best efficacy of all type treatments(in terms of overall survival and disease free survival). these treatments are based on an induction phase with reinforced cyclophosphamide and l-asparaginase, and a re-use of the first drugs after consolidation (delayed intensification). the prognostic factors of all are now better defined, determining risk groups. according to these prognostic indicators, the allograft could be proposed in first complete remission. indicators are biological (hyperleukocytosis, chromosomal abnormalities as t(4;11), t(9;22), t(1;19) translocations), clinical (central nervous system involvement), evolutive (salvage therapy needed to obtain complete remission), consideration of early response (cortico-sensibility and chemo-sensibility) and molecular responses (residual disease). on the other hand, the prognostic factors of ll are not well known. this study should permit to better define them. so the prognostic indicators of all, in this study, will be decisional for the indication of allograft. this treatment is based on a parallel currently recruiting adult patients with all (protocol graall 2003).

Eligibility criteria:
inclusion criteria: * patient with lymphoblastic lymphoma. * aged from 18 to 59 years. * medullary blasts rate less than 20% * non previously treated * with or without central nervous system or meningeal involvement. * no contra-indication to anthracyclines. * no contra-indication to intensive treatments * negative hiv serology test * negative pregnancy test for all female patients of childbearing potential. * able to be regularly followed up. exclusion criteria: * evolutive cancer with the exception of non melanoma skin tumours or stage 0 (in situ) cervical carcinoma. * prior treatment with chemotherapy. * lymphoblastic transformation of chronic myeloid leukaemia * patient unable to be regularly followed-up.

Keywords: non-hodgkin lymphoma lymphoblastic
this phase ii/iii, multicenter study is designed to evaluate the safety and clinical activity of al3810 in patients

Conditions: Extensive-stage Small Cell Lung Cancer

Summary: phase ii study is to evaluate the safety and tolerability of al3810 in combination with carboplatin plus (+) etoposide in untreated participants with es-sclc. phase iii study is to evaluate the efficacy of al3810 in combination with carboplatin plus (+) etoposide in untreated participants with es-sclc.


Eligibility criteria:
inclusion criteria: * signed informed consent form * male or female, 18 \~75years of age * eastern cooperative oncology group(ecog) performance status of 0 or 1 * histologically or cytologically confirmed es-sclc * no prior treatment for es-sclc * measurable disease, as defined by recist v1.1 * adequate hematologic and end organ function. * serum pregnancy test in screening period for women of childbearing potential should be negative.except for women who have a history of sterilization or are postmenopausal.men or woman subjects of reproductive age and their partners must agree to use effective contraception for at least 6 months from the date of signing the informed consent form(icf) until the last dose of the investigational therapy. exclusion criteria: main exclusion criteria * histologically confirmed mixed small cell lung cancer. * symptoms related to central nervous system(cns) metastasis, unstable cns metastasis, or cns diseases needed the increase of steroid dosage to control. * uncontrolled hypertension.
study to determine the pharmacokinetics, safety & tolerability of aripiprazole in adults with schizophrenia

Conditions: Schizophrenia

Summary: this trial will determine the pharmacokinetics, safety and tolerability of single-dose aripiprazole administered intramuscularly in adults with schizophrenia


Eligibility criteria:
inclusion criteria: * male and female individuals between 18 and 64 years, inclusive, at screening with a current diagnosis of schizophrenia as defined by diagnostic and statistical manual of mental disorders: edition 5 (dsm-5) * body mass index (bmi) between 18 and 35 kg/m\^2 at screening * male and female subjects who are surgically sterile, female subjects who have been postmenopausal for at least 12 consecutive months prior to screening or male/female subjects who agree to remain abstinent or practice 2 of the approved birth control methods from screening for at least 150 days after dose of investigational medical product (imp) for female subjects or 180 days after dose of imp for male subjects. * documented history of previously tolerating aripiprazole per investigator's judgment. exclusion criteria: * met dsm-5 criteria for substance use disorder within past 180 days * positive drug screen for drugs of abuse * use of more than 1 antipsychotic medication at screening or baseline, except for oral aripiprazole administered during tolerability testing and current antipsychotic medication * subjects may not receive varenicline beyond the screening visit. * subjects who had participated in any clinical trial involving a psychotropic medication within 1 month prior to administration of imp * major surgery within 30 days prior to administration of imp or surgery during the trial * subjects at significant risk of committing suicide based on history, psychiatric exams * subjects currently in an acute relapse of schizophrenia * subjects with a current dsm-5 diagnosis other than schizophrenia * subjects with a history of neuroleptic malignant syndrome, seizure disorder, or clinically significant tardive dyskinesia * subjects who have had electroconvulsive therapy within 2 months prior to administration of imp * females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving imp * history of or current hepatitis or acquired immunodeficiency syndrome or carriers of hepatitis b surface antigen (hbsag), hepatitis c antigen (anti-hcv) and/or human immunodeficiency virus (hiv) antibodies
evaluation of factors in human brain tumors

Conditions: Brain Neoplasm; Glioblastoma; Glioma; Pituitary Neoplasm

Summary: presently, patients with primary malignant brain tumors have a life expectancy of 15 weeks following surgery unless they receive additional types of therapy (chemotherapy, radiotherapy, and/or immunotherapy). patients that receive additional therapy can increase life expectancy to 50 weeks. the statistics on the life expectancy and survival have increased efforts among researchers to develop new treatments for primary malignant brain tumors. this research project involves the growth and study of human brain tumor cells outside the body in the laboratory as part of an attempt to better understand these tumors and to develop more effective treatments for them.

this protocol involves the study of human brain tumor cells outside the body in the laboratory as part of an attempt to better understand these tumors and to develop more effective therapeutic measures. malignant primary brain tumor patients at present have a life expectancy of approximately 15 weeks following surgery unless other adjunctive measures are taken. with currently available adjunctive therapy the life expectancy reaches 50 weeks. these survival data have spurred extensive efforts to develop new treatment modalities. radiation, chemotherapy and immunotherapy have been mildly helpful adjuncts but their use has been largely on empirical grounds or on the basis of experimentation on animal tumor models often quite different in nature from human brain tumors. our group has sought to develop data upon which to devise new treatment strategies for patients with malignant brain tumors. the foundation of our approach rests upon the use of in vitro studies of the cell biology of each patient's tumor. it is our plan to utilize these tumors for in vitro investigation of the immunology, biology, biochemistry and molecular biology of brain tumors. optimal conventional therapy will be given to the patients as we seek to learn more of how the scientific information obtained can be used to help them.

Eligibility criteria:
inclusion criteria: patients to be studied will have either undergone surgical confirmation of a malignant primary brain tumor or be considered likely to have that diagnosis on the basis of diagnostic studies. they should have survival likelihood of at least three months and be able to comprehend the nature of the proposed program.

Keywords: brain tumors glioma glioblastoma multiforme pituitary adenoma
phase 1 study to evaluate antiviral activity of small molecule direct antiviral agent at multiple doses in subjects with chronically infected hepatitis c virus.

Conditions: Hepatitis, Chronic; Hepatitis C Virus

Summary: phase 1 study in hvc (hepatitis c virus) infected subjects to determine pharmacokinetics, safety and efficacy in subjects with no or inadequate response to prior treatment.


Eligibility criteria:
inclusion criteria: hcv positive with hcv rna\>100,000 iu/ml genotype 1; cohort a- non responders or partial exclusion criteria: hiv hbv co-infection decompensated liver disease liver disease due to causes other than hcv, afp\>200ng/ml
evaluation of 3d overlay during transjugular intrahepatic portosystemic shunt (tips) procedure

Conditions: Portal Hypertension

Summary: the goal of this study is to evaluate an alternate approach, which involves using a 3d puncture path overlay, to access the portal vein during a transjugular intrahepatic portosystemic shunt (tips) procedure. the study should determine if the alternate approach provides these benefits: improved safety of procedure, and reduced intervention time (including reduction of radiation exposure), which benefits both interventional radiologist and the patient. during a tips procedure, a shunt or stent (mesh tube) is passed down the jugular vein (the vein above the collarbone in the neck) using fluoroscopy (x-ray) guidance. the shunt then is inserted between the portal vein (vein that carries blood from the digestive organs into the liver) to a hepatic vein (vein that carries blood away from the liver back to the heart). in the standard approach, the interventional radiologist uses two-dimensional guidance (2d - having the dimensions of height and width only) to locate the path between the portal vein and hepatic vein. however, since these two veins do not connect, this method does not provide information on the three-dimensional (3d) relationship between the two veins. in the alternate approach, the physician will have the option of using 3d guidance to locate the path. an on-table limited (small field of view) ct scan, used in combination with fda approved imaging software, will provide a 3d image demonstrating the relationship between the portal vein and the hepatic vein. the 3d image is overlaid on the standard live x-ray images to assist in needle guidance during the tips procedure. the ct scan performed will be in place of the angiograms that are typically performed. however, if the portal vein is not adequately seen in the ct images, the angiograms will be done and there will be no overlay. the procedure will proceed using the standard approach.


Eligibility criteria:
inclusion criteria: * prospective study of 20 patients, age 18 years or older, scheduled for clinically indicated tips procedure. patients must be capable of providing informed consent. exclusion criteria: * does not meet inclusion criteria. * portal vein does not opacify
changes of cerebral glucose metabolism and after 12 weeks of escitalpram treatment in panic disorder

Conditions: Panic Disorder

Summary: panic disorder is one of the most prevalent psychiatric disorders and recently abnormal fear network is known to be implicated in the pathophysiology of panic disorder. the fear network involves many brain regions such as amygdala, hippocampus, periaqueductal gray (pag), locus coeruleus, parahippocampal gyrus, frontal cortex, and thalamus. escitalopram, a highly selective serotonin reuptake inhibitor, is usually effective for panic dis order, but there is little information on how escitalopram affects the fear network. the specific aim of this study is to test the following hypotheses using 18f-fdg positron emission tomography (pet) 1. patients with panic disorder will show abnormal activity of the fear network compared to healthy comparison subjects. 2. patients with panic disorder will show normalized activity of the fear network after 12-weeks of treatment with escitalopram. 3. the changes of fear work after the treatment will be associated with psychological variables and neurohormones.


Eligibility criteria:
inclusion criteria: * panic disorder * 20-60 years exclusion criteria: * history of major psychosis (schizophrenia or bipolar disorder), social phobia, obsessive-compulsive disorder, and generalized anxiety disorder, and posttraumatic stress disorder. the acceptable score on the 17-item hamilton depression rating scale at entry into the study will be less than 17. * patients and volunteers with alcohol dependence and current regular use of benzodiazepines will be excluded. subjects with current or previous regular use of benzodiazepines will be excluded.

Keywords: panic disorder pet escitaopram
the effect of omega-3 on selected cytokines involved in cytokine storm

Conditions: Cytokine Storm; Cytokines

Summary: the trial was designed to assess the effect of daily dose of 300 mg omega-3 supplements for 2 months on the selected interleukins levels in uninfected people with covid-19.

omega-3 fatty acids (omega-3) are long poly unsaturated fatty acids that can be found in plants and fish, its refer to a group composed of three type of fatty acids called: eicosapentaenoic acid (epa), alpha-linoleic acid (ala), and docosahexaenoic acid (dha) . the health promoting effect of n-3fa may be due to immune modulating and anti-inflammatory actions . the anti-inflammatory properties of n-3fa are used for treatment of the inflammatory diseases such as irritable bowel syndrome, rheumatoid arthritis, eczema, and psoriasis . many studies reported a significant reduction in the risk of cancers in breast, prostate, ovaries with supplementation of n-3fa (larsson et al. 2004) .however, high-doses omega-3 supplements such as 1000 mg/day are widely spread in community pharmacies in jordan . currently , community pharmacy around the world are facing the challenge of increased demand for care of uninfected people with covid -19. accordingly , the current randomized clinical trial was designed to evaluate the effect of daily 300 mg of omega 3-fa supplements on the immune health status of uninfected people with covid-19 as a part of as a part of preventive health care . therefore , this rct aims to assess whether regular daily dose of regular daily dose of omega 3-fa (300 mg) for 2 months supplementation against covid-19 infection as a part of preventive treatment protocol in uninfected jordanian peoples. the investigators hypothesize that the regular dose of omega 3-fa (300 mg) /day for 2 months will significantly change immune responses compared with the control group.

Eligibility criteria:
inclusion criteria: * inclusion criteria included males and females in the age range of 30-66 years without a medical diagnosis of covid-19 infection. exclusion criteria: * exclusion criteria included males or females diagnosed with any chronic immune problems, including autoimmune diseases, chronic or severe infections. * pregnant, breastfeeding, and females using hormonal contraceptives were also excluded.

Keywords: covid-19 il-1 beta il-6 tnf alpha omega-3 n-3fa uninfected